Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Rating) – Research analysts at SVB Leerink decreased their Q2 2022 EPS estimates for shares of Tango Therapeutics in a research note issued on Wednesday, May 11th. SVB Leerink analyst A. Berens now anticipates that the company will post earnings per share of ($0.33) for the quarter, down from their prior estimate of ($0.31). SVB Leerink also issued estimates for Tango Therapeutics’ Q3 2022 earnings at ($0.37) EPS, Q4 2022 earnings at ($0.41) EPS, FY2022 earnings at ($1.41) EPS, FY2023 earnings at ($1.78) EPS, FY2024 earnings at ($2.17) EPS, FY2025 earnings at ($2.52) EPS and FY2026 earnings at ($2.36) EPS.
Tango Therapeutics (NASDAQ:TNGX – Get Rating) last issued its quarterly earnings results on Monday, March 28th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The company had revenue of $5.72 million during the quarter, compared to the consensus estimate of $6.12 million.
Shares of NASDAQ TNGX opened at $5.07 on Monday. Tango Therapeutics has a 52 week low of $4.41 and a 52 week high of $18.84. The stock’s fifty day moving average is $7.35 and its 200 day moving average is $9.18.
A number of institutional investors have recently added to or reduced their stakes in the business. Citigroup Inc. bought a new position in Tango Therapeutics in the third quarter valued at about $41,000. Marshall Wace LLP bought a new position in Tango Therapeutics in the fourth quarter valued at about $68,000. Swiss National Bank grew its position in Tango Therapeutics by 7.4% in the first quarter. Swiss National Bank now owns 93,100 shares of the company’s stock valued at $706,000 after acquiring an additional 6,400 shares during the last quarter. Penserra Capital Management LLC bought a new position in Tango Therapeutics in the third quarter valued at about $133,000. Finally, Arizona State Retirement System bought a new position in Tango Therapeutics in the fourth quarter valued at about $116,000. Hedge funds and other institutional investors own 77.28% of the company’s stock.
About Tango Therapeutics (Get Rating)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
- Get a free copy of the StockNews.com research report on Tango Therapeutics (TNGX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.